Cardioneuroablation (CNA) is now recognized as a safe and effective method in patients with cardioinhibitory neurocardiogenic syncope (CNCS), especially in young patients in order to avoid or prolong, as much as possible, the timing of definitive cardiac pacing. Several investigations have shown beneficial and very satisfactory results with a standard non-extensive endocardial ablation, aimed at identifying high-amplitude fragmented signals in the right and left atria. Despite this, the current scientific debate is focused about a proposal on an ablative method, even more individualized than CNA (at least as a first approach), considering that a standardized approach, especially in the left atrium, could expose CNCS patients with a good prognosis to an excessive risk of complications. These findings, moving from the concept of CNA to a new concept of 'cardioneuromodulation', opened a new era, aimed at a non-extensive and individualized treatment of different clinical CNCS scenarios or vagally-mediated atrioventricular block or sinus-atrial node dysfunction.
Radiofrequency catheter ablation of the cavotricuspid isthmus is the standard treatment for patients suffering from typical atrial flutter. The aim of this study was to test the feasibility of tissue thickness and lesion transmurality measurement by a novel dielectric system. This was a retrospective multicentric non-randomized open-label, single-arm study. The atrial wall thickness was significantly higher close to the tricuspid annulus than close to the inferior vena cava and a trend towards a progressive decrease of atrial wall thickness was observed moving the mapping catheter from the tricuspid valve to the inferior vena cava. The possibility to visualize the tissue thickness could modify the way to deliver radiofrequency energy, allowing a tailored approach in cardiac ablation procedures.
For several years, the autonomic nervous system has played a central role in the pathophysiological mechanism of atrial fibrillation (AF), so much so that it has been considered one of the cornerstones of Coumel's triangle. The clinical and therapeutic management of AF secondary to sympatho-vagal imbalance represents one of the most important examples of how precision medicine should be applied. Increasing knowledge of this kind of arrhythmias has made it possible to select specific antiarrhythmic drugs and to diversify their use according to vagal or adrenergic AF forms. Ablative strategies, such as cardioneuroablation and non-direct cardiac neuromodulation methods (such as renal denervation and peripheral vagal stimulation), have gradually emerged. In the possibly near future, there will be a development of new acquisitions regarding new pharmacological therapeutic strategies and gene therapy. Finally, finding an AF in patients experiencing syncopal episodes opens a whole chapter regarding interesting, but also complex, diagnostic and therapeutic strategies, ranging from neurally mediated forms to convulsive seizure that could also increase the risk of sudden death.
Arrhythmogenic substrate, modulating factors, and triggering factors (the so-called Coumel's triangle concept) play a primary role in atrial fibrillation (AF) pathophysiology. Several years have elapsed since Coumel and co-workers advanced the concept of the relevance of autonomic nervous system (ANS) influences on atrial cells' electrophysiological characteristics. The ANS is not only associated with cardiac rhythm regulation but also exerts an important role in the triggering and maintenance of atrial fibrillation. This review aims to describe in detail the autonomic mechanisms involved in the pathophysiology of atrial fibrillation (AF), starting from the hypothesis of an "Autonomic Coumel Triangle" that stems from the condition of the fundamental role played by the ANS in all phases of the pathophysiology of AF. In this article, we provide updated information on the biomolecular mechanisms of the ANS role in Coumel's triangle, with the molecular pathways of cardiac autonomic neurotransmission, both adrenergic and cholinergic, and the interplay between the ANS and cardiomyocytes' action potential. The heterogeneity of the clinical spectrum of the ANS and AF, with the ANS playing a relevant role in situations that may promote the initiation and maintenance of AF, is highlighted. We also report on drug, biological, and gene therapy as well as interventional therapy. On the basis of the evidence reviewed, we propose that one should speak of an "Autonomic Coumel's Triangle" instead of simply "Coumel's Triangle".
Fabry disease (FD) is a rare X-linked inherited lysosomal storage disorder caused by deficient a-galactosidase A activity that leads to an accumulation of glycolipids, mainly globotriaosylceramide (Gb3) and globotriaosylsphingosine, in affected tissues, including the heart. Cardiovascular involvement usually manifests as left ventricular hypertrophy (LVH), myocardial fibrosis, heart failure, and arrhythmias, which limit the quality of life and represent the most common causes of death. Following the introduction of enzyme replacement therapy, early diagnosis and treatment have become essential in slowing down the disease progression and preventing major cardiac complications. Recent advances in the understanding of FD pathophysiology suggest that in addition to Gb3 accumulation, other mechanisms contribute to the development of cardiac damage. FD cardiomyopathy is characterized by an earlier stage of glycosphingolipid accumulation and a later one of hypertrophy. Morphological and functional aspects are not specific in the echocardiographic evaluation of Anderson-Fabry disease. Cardiac magnetic resonance with tissue characterization capability is an accurate technique for the differential diagnosis of LVH. Progress in imaging techniques has improved the diagnosis and staging of FD-related cardiac disease: a decreased myocardial T1 value is specific of FD. Late gadolinium enhancement is typical of the later stage of cardiac involvement but as in other cardiomyopathy is also valuable to predict the outcome and cardiac response to therapy.
Abstract Funding Acknowledgements Type of funding sources: None. Backgorund: Intermittent ventricular pre-excitation was considered a low-risk marker for sudden death. However, to date some studies do not exclude the existence of accessory pathways (APs) with high-risk intermittent antegrade conductive properties. High-risk features of APs are: ERP/SPERRI ≤250 msec (in basal or during adrenergic stimulus), inducibility of atrioventricular reciprocating tachycardias (AVRT), inducibility of pre-excited atrial fibrillation (AF), multiple APs. For these catheter ablation is recommended. Purpose The aim of this retrospective study was to evaluate the existence of a statistically significant difference in the risk characteristics between patients with intermittent pre-excitation (IPX) and with persistent pre-excitation (PPX), from a sample of adults with symptomatic ventricular pre-excitation (Wolff-Parkinson-White Syndrome). Methods Between August 2005 and December 2015, 293 adults (age ≥18 years) [males: 183 (62.5%)], without structural heart disease, with signs of ventricular pre-excitation and symptomatic for palpitations underwent an EP study [IPX: 51 (17.4%), males: 31 (60.8%); PPX: 242 (82.6%), males: 152 (62.8%)]. The APs were submitted to catheter ablation if EP study showed inducibility of arrhythmias (AVRT/AF) and, in case of non-inducibility of arrhythmias, if ERP ≤250 msec, in basal or during intravenous infusion of isoproterenol. Additionally, the presence of multiple accessory pathways was assessed during the test. Results The 2 groups of patients did not show statistically significant differences in age at the time of EP study [IPX: mean age 37.23±16.89 years Vs PPX: mean age 39.03±16.19 (P-value>0.05)] and gender (IPX male: 60.8% Vs PPX male: 62.8%; P-value>0.05). When measured, there were no statistically significant differences regarding ERP [IPX: mean ERP 260±45.8msec Vs PPX: mean ERP 267.7±59.6msec; P-value>0.05]. The inducibility of arrhythmias (AVRT/AF) was 59.3% in the IPX group (27 patients) vs 38% in the PPX group (92 patients), showing statistically significant differences (P-value<0.05). Multiple accessory pathways were found in 2 patients of the IPX group (3.9%), both females (100%), and in 6 patients of the PPX group (2.5%), of which 2 females (33.3%), not showing statistically significant differences (P-value>0.05). Conclusion In our study, patients with IPX did not shown statical significant differences in clinical and electrophysiological features Vs PPX partients. Thus, intermittent ventricular pre-excitation could not absolutely be considered a marker of lower arrhythmic risk.
Magnetic resonance (MR) represents a new interesting imaging approach for guiding electrophysiology (EP)-based ablation procedures of atrial flutter and typical atrial fibrillation. This new approach permits to reach good results if compared with conventional EP ablation. Tissue characterization by MR permits to detect cardiac anatomy and pathological substrate like myocardial scars well visualized with late gadolinium enhancement (LGE) sequences. Intra-procedural imaging is useful to real-time follow the catheter during the ablation procedure and at the same time to visualize cardiac anatomy in addition to understanding if the ablation is correctly performed using oedema sequences. Performing cardiac ablations inside an MR room permits to reduce radiation exposure and occupational illnesses.
Advances in cardiac implantable electronic devices (CIEDs) have prolonged life expectancy in various medical settings. However, the issue of hypersensitivity to components of CIEDs is still a concern. Since 1970, allergic reactions to metallic and nonmetallic components of CIEDs have been reported. Hypersensitivity reactions to medical devices are rare and not fully understood. In some cases, diagnosis and treatment are difficult. Cardiologists should always keep in mind pacemaker allergy when a patient appears with wound complications and no signs of infection. Patch testing should be tailored toward the specific biomaterials used in a device, in addition to testing with standard screening allergens in select cases.
AbstractBackgroundHis bundle pacing (HBP) may be a challenging procedure, often involving a long fluoroscopic time (FT) and a long procedural time (PT). We sought to evaluate whether the use of a new nonfluroscopic mapping (NFM) system, the KODEX‐EPD, is able to reduce FT and PT when mapping is performed by the pacing catheter rather than an electrophysiological mapping catheter.Methods and ResultsWe included 46 consecutive patients (77 ± 8 years; 63% male) who underwent HBP; in 22 a NFM‐guided procedure with the KODEX‐EPD system was performed (group 1), whereas in 24 a conventional fluoroscopy‐guided approach was used (group 2). Pacing indications were sick sinus syndrome in 13, atrioventricular block in 21, and cardiac resynchronization therapy in 12 cases. Both a lumen‐less fixed helix lead and a stylet‐driven extendable helix lead were used, respectively, in 24% and 76% of patients. HBP was successful in 22 patients (100%) in group 1 and 23 patients (96%) in group 2. The FT was significantly reduced in group 1 (183 ± 117 s vs 464.1 ± 352 s in group 2, p = .012). There were no significant differences between groups in PT and other procedural outcomes.ConclusionsThe KODEX‐EPD system may be safely used in HBP procedures. It is effective in reducing ionizing radiation exposure, as evidenced by the significant drop in FT, without increasing PT.
Catheter ablation of cardiac arrhythmias is usually performed through the femoral venous approach. Systemic venous return anomalies such as interruption of the inferior vena cava may represent a challenge during electrophysiological procedures.A 55-year-old patient with previous surgical correction of abnormal pulmonary venous return was admitted for poorly tolerated atrial flutter recurrences. He also had an interrupted inferior vena cava continuing as azygos vein and left superior vena cava draining via coronary sinus into the right atrium. Cavotricuspid isthmus radiofrequency ablation was successfully performed through the persistent left superior vena cava using a three-dimensional (3D) electroanatomical mapping system.Despite systemic venous abnormalities may potentially have important implications during electrophysiological procedures, arrhythmias can be successfully ablated with the aid of 3D electroanatomical mapping systems.
The autonomic nervous system (ANS) is known to play an important role in the genesis and maintenance of atrial fibrillation (AF). Biomolecular and genetic mechanisms, anatomical knowledges with recent diagnostic techniques acquisitions, both invasive and non-invasive, have enabled greater therapeutic goals in patients affected by AF related to ANS imbalance. Catheter ablation of ganglionated plexi (GP) in the left and right atrium has been proposed in varied clinical conditions. Moreover interesting results arise from renal sympathetic denervation and vagal nerve stimulation. Despite all this, in the scenario of ANS modulation translational strategies we necessary must consider the treatment or correction of dynamic factors such as obesity, obstructive sleep apnea, lifestyle, food, and stress. Finally, new antiarrhythmic drugs, gene therapy and "ablatogenomic" could be represent exciting future therapeutic perspectives.
Background: Catheter ablation is the established treatment for patients with symptomatic Wolff- Parkinson-White syndrome (WPW). However, some patients undergo a challenging ablation or have recurrences during the early post-ablation phase. The aim of this study was to evaluate the clinical factors associated with an unsuccessful ablation outcome or repeated sessions. Methods: Four hundred seventy-five symptomatic consecutive WPW patients (38.2 +/- 16.2 years old, 61% men, 69% with pre-excitation) who underwent an accessory pathway (AP) ablation from August 2005 to December 2015 were enrolled. When APs recurred, a redo ablation procedure was performed according to the patients' desire. Results: Four hundred thirty-nine patients (92.4%) were cured by ablation, but it failed in 36 (7.6%) after the first procedure. Seventeen patients had AP recurrences during the acute phase within 36 h post -ablation. On the other hand, 4 were identified after more than one year. In a multivariate logistic regression analysis, multiple, parahisian, and broad APs were significant independent predictors of recurrences after the 1st procedure, with odds ratios of 14.88 (p < 0.001), 10.14 (p < 0.001), and 6.88 (p < 0.001), respectively. Finally, 468 patients (98.5%) received a successful ablation during a mean follow-up of 8.3 +/- 3.0 years. However, after the final procedure no significant predictors were recognized. Out of 508 total procedures, three major (0.6%) complications occurred. Conclusions: Symptomatic WPW patients with multiple, parahisian, and broad APs had a significantly higher risk of recurrence. In half of the recurrence patients, AP recurrences were confirmed during the acute phase, but were rarely recorded in the very late phase. (c) 2020 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Several reports have focused on biatrial ganglionated plexi (GP) transcatheter ablation to treat cardioinhibitory neurocardiogenic syncope (CNS). Considering that anatomical studies showed a significant number of GP in the right atrium (RA), we hypothesized that RA “cardioneuroablation” could be an effective treatment for CNS. Eighteen consecutive patients (mean age: 36.9 ± 11.2 years) with severe CNS were submitted to transcatheter ablation of GPs in the RA alone using an anatomical approach. Head up tilt test evaluation was performed during the follow-up period at 6, 12, and 24 months and in case of significant symptoms, while heart rate variability parameters were evaluated at patients discharge at 1, 3, 6, 12, 24, and 36 months after ablation. At a mean follow-up of 34.1 ± 6.1 months, 3 (16.6%) patients experienced syncopal episodes and 5 patients (27.7%) only prodromal episodes. Syncopal and prodromal recurrences were significantly decreased both in overall population (P = 0.001) and in symptomatic patients after ablation (P = 0.003). Heart rate variability analysis showed the loss of autonomic balance secondary to a reincrease of sympathetic tone after the acute phase faster than vagal tone more evident at 12 months (LF/HF vs preablation, P < 0.001) and persistent until 24 months. Finally, a good correlation was observed between symptomatic events and the extension of RF lesions in supero-, middle-, and infero-posterior RA areas (r = 0.73, P = 0.03; r = 0.85, P = 0.02; r = 0.87, P = 0.004, respectively). Cardioneuroablation in the RA can be considered safe and an effective technique to treat CNS episodes.
PURPOSE:Electroanatomical mapping (EAM) could increase cardiac magnetic resonance imaging (CMR) sensitivity in detecting ventricular scar. Possible bias may be scar over-estimation due to inadequate tissue contact. Aim of the study is to evaluate contact-force monitoring influence during EAM, in patients with idiopathic right ventricular arrhythmias.METHODS:20 pts (13 M; 43 ± 12 y) with idiopathic right ventricular outflow tract (RVOT) arrhythmias and no structural abnormalities were submitted to Smarttouch catheter Carto3 EAM. Native maps included points collected without considering contact-force. EAM scar was defined as area ≥1 cm2 including at least 3 adjacent points with signal amplitude (bipolar <0.5 mV, unipolar 3,5 mV), surrounded by low-voltage border zone. EAM were re-evaluated offline, removing points collected with contact force <5 g. Finally, contact force-corrected maps were compared to the native ones.RESULTS:An EAM was created for each patient (345 ± 85 points). After removing poor contact points, a mean of 149 ± 60 points was collected. The percentage of false scar, collected during contact force blinded mapping compared to total volume, was 6.0 ± 5.2% for bipolar scar and 7.1 ± 5.9% for unipolar scar, respectively. No EAM scar was present after poor contact points removal. Right ventricular areas analysis revealed a greater number of points with contact force < 5 g acquired in free wall, where reduced mean bipolar and unipolar voltage were recorded.CONCLUSIONS:To date this is the first work conducted on structurally normal hearts in which contact-force significantly increases EAM accuracy, avoiding "false scar" related to non-adequate contact between catheter and tissue.
BACKGROUND:The Amigo® Remote Catheter System is a relatively new robotic system for catheter navigation. This study compared feasibility and safety using Amigo (RCM) versus manual catheter manipulation (MCM) to treat paroxysmal atrial fibrillation (PAF). Contact force (CF) and force-time integral (FTI) values obtained during pulmonary vein isolation (PVI) ablation were compared.METHODS:Forty patients were randomly selected for either RCM (20) or MCM (20). All were studied with the Thermocool® SmartTouch® force-sensing catheter (STc). Contact Force (CF), Force Time Integral (FTI) and procedure-related data, were measured/stored in the CARTO®3.RESULTS:All cases achieved complete PVI without major complications. Mean CF was significantly higher in the RCM group (13.3 ± 7.7 g in RCM vs. 12.04 ± 7.42 g in MCM p < 0.001), as was overall mean FTI (425.6 gs ± 199.6 gs with RCM and 407.5 gs ± 288.0 gs in MCM (p = 0.007) and was more likely to fall into the optimal FTI range (400-1000) using RCM (66.1% versus 49.1%, p < 0.001). FTI was significantly more likely to fall within the optimal range in each PV, as was CF within its optimal range in the right PVs, but trended higher in the left PVs. Freedom from atrial tachyarrhythmia was 90.0% for the RCM and 70.0% for the MCM group (p = 0,12) at 540 days follow-up.CONCLUSIONS:This pilot study suggests that use of the Amigo RCM system, with STc catheter, seems to be safe and effective for PVI ablation in paroxysmal AF patients. A not statistically significant favorable trend was observed for RCM in term of AF-free survival.
Background: Left bundle branch block (LBBB) and left axis deviation (LAD) patients may have poor response to resynchronization therapy (CRT). We sought to assess if LBBB and LAD patients show a specific pattern of mechanical asynchrony. Methods: CRT candidates with non-ischemic cardiomyopathy and LBBB were categorized as having normal QRS axis (within -30 degrees and +90 degrees) or LAD (within -30 degrees and -90 degrees). Patients underwent tissue Doppler imaging (TDI) to measure time interval between onset of QRS complex and peak systolic velocity in ejection period (Q-peak) at basal segments of septal, inferior, lateral and anterior walls, as expression of local timing of mechanical activation. Results: Thirty patients (mean age 70.6 years; 19 males) were included. Mean left ventricular ejection fraction was 0.28 +/- 0.06. Mean QRS duration was 172.5 +/- 13.9 ms. Fifteen patients showed LBBB with LAD (QRS duration 173 +/- 14; EF 0.27 +/- 0.06). The other 15 patients had LBBB with a normal QRS axis (QRS duration 172 +/- 14; EF 0.29 +/- 0.05). Among patients with LAD, Q-peak interval was significantly longer at the anterior wall in comparison to each other walls (septal 201 +/- 46 ms, inferior 242 +/- 58 ms, lateral 267 +/- 45 ms, anterior 302 50 ms; p < 0.0001). Conversely, in patients without LAD Q-peak interval was longer at lateral wall, when compared to each other (septal 228 Jr 65 ms, inferior 250 64 ms, lateral 328 +/- 98 ms, anterior 291 +/- 86 ms; p < 0.0001). Conclusions: Patients with heart failure, presenting LBBB and LAD, show a specific pattern of ventricular asynchrony, with latest activation at anterior wall. This finding could affect target vessel selection during CRT procedures in these patients. (C) 2017 Elsevier Inc. All rights reserved.
BackgroundThird-generation cryoballoon (CB3) is characterized by a 40% shorter distal tip designed to increase the rate of pulmonary veins real-time signal recording in order to measure time necessary to isolate veins, the “Time to effect” (TTE). Few data are currently available on clinical follow up of CB3 treated patients.MethodsSixtyeight consecutive patients (mean age 57.8 ± 9.6 years, 48 male) with paroxysmal or persistent atrial fibrillation (AF) were enrolled. Thirthyfour (25 paroxysmal AF) underwent to a 28 mmCB3 pulmonary veins isolation and were compared to 34 treated (21 paroxysmal AF) with 28 mmCB2.ResultsCB3 use was correlated to significant increase of the possibility to measure TTE in every treated veins (left superior 82,35% vs 23,53%, left inferior 70,59% vs 38,24%, right superior 58,82% vs 14,71%, right inferior 52,94% vs 17,65%). When it is measured, TTE wasn't different between two groups. Higher nadir temperature was observed in CB3 patients (−39.4 ± 5.2 °C vs −43.0 ± 7.2 °C, p = 0.03). CB3 procedures were shorter (91.4 ± 21.7 vs 110.9 ± 31.8 min, p = 0.018), with a significant reduction in cryoenergy delivery time (24.2 ± 8.5 vs 20.3 ± 6.7 min, p < 0.05), and a significant reduction in left atrium dwell time (59.3 ± 9.8 vs 69.3 ± 10.8 min, p = 0.02, p < 0.05). At one year follow up period the Kaplan-Meier curve didn't show any significant difference in AF-free survival (Log p = 0,49).ConclusionsNovel CB3 is a useful tool in order to simplify AF cryoballoon ablation when compared to second generation cryoballoon, as observed in our experience. Follow up data seem confirm a clinical CB3 efficacy at least comparable CB2.
A case of a 31 years old woman volleyball player highly symptomatic for arrhythmic palpitations is reported.The woman was disqualified from competitive sport and referred to our centre for atrial fibrillation (AF) ablation.During symptoms surface ECG had documented irregular supraventricular tachyarrhythmia interpreted as AF.Electrophysiological study could reveal double-His conduction as the true arrhythmia mechanism and the patient was successfully treated with nodal slow pathway ablation.Patient was totally asymptomatic at a 12 months follow up and he was readmitted to competitive sport.The case further underlines the concept that young subjects with suspected lone AF should undergo to a careful clinical evaluation in order to reconstruct the exact electrophysiological mechanism to plan a safe and effective therapy.
Aim: The new miniaturized Insertable Cardiac Monitors (mICMs) simplified implant procedure and increased physician and patient acceptance. Besides size reduction, mICM has been provided with fully automatic daily remote transmission capabilities. The aim of this observational study was to assess the efficiency of this new mICM provided with a daily remote monitoring (RM) system in comparison to standard ICM (sICM) followed-up monthly. Methods: A total of 180 patients with an ICM were followed from April 2010 to May 2015: 107 pts with the mICM and 73 pts with sICM. The mICM implantations started on January 2015. The principal indications for total ICM implantation were syncope (68%), pre-syncope (13%) palpitations (13%), AF-management (14%) or suspected AF/cryptogenetic stroke (9%). Results: A significant event was diagnosed in 53.9% of patients (62.6% mICM vs 41.1% sICM). The most frequent event in diagnosed population was tachycardia > 120 bpm in 40.4% of cases (37.3% mICM vs 48.1% sICM). In 36% of patients, asystole > 3 sec or bradycardia < 30 bpm was recorded. Symptoms in absence or with slight variation in rhythm were present in 22.1% of patients. 54.2% of patients did not need any office visits to obtain diagnosis (mICM 69.4% vs sICM 9.5%), 33.7% of patients needed 1 office visit (mICM 25.8% vs sICM 57.1%), 8.4% of patients needed 2 office visits (mICM 1.6% vs sICM 28.6%), 3.6% of patients needed 3 office visits (mICM 3.2% vs sICM 4.8%). The mean time from the start of RM to onset of symptoms was 48.8 days (29.7 days for mICM vs 76.8 days for sICM group). The mean time from the first symptoms to treatment was 3.1 days (2.3 days for mICM vs 4.3 days for sICM). The average of total events has amounted to 1068.2 events (mICM 218.1 vs sICM 2386.6), of which 558.4 false events (mICM 100.7 vs sICM 1268.1). The average of events until the diagnosis has been 119 events (mICM 61.7 vs sICM 263.4), of which 59.2 false events (mICM 18.2 vs sICM 162.3). Conclusion: Automated daily remote monitoring of mICM was associated with presented more diagnostic accuracy than previous model with a minor count of total transmitted events, false events and office visits until diagnosis. The use of mICM allowed to save manpower compared to sICM with substantial economic benefits.
Introduction: Catheter ablation (CA) is an established treatment for symptomatic drug refractory AF. Albeit for paroxismal AF the PVI alone is effective in maintaining sinus rhythm (SR), for sustained AF forms the success of CA is limited and the understanding of substrate remains unclear. Methods: The study population included 71 patients with long lasting persistent AF (> 12 months) undergone CA (PVI + ibutilide-guided CFAEs ablation). If AF was not terminated during CA, electrical cardioversion (CV) was performed 4 weeks later. Rate of sustained recurrencies requiring CV have been evaluated at a mean follow-up of 40.1 ± 18.5 months. Conclusion: At long term follow-up SR is achievable with CA in the majority of patients with long lasting persistent AF. Usually a re-do CA or a CV is required.